INTESTINE Vol.6 No.3(5)

特集名 大腸カルチノイド -- 最新の治療戦略
題名 内科的治療の適応と限界
発刊年月 2002年 05月
著者 広中 秀一 国立がんセンター東病院消化器内科
著者 吉田 茂昭 国立がんセンター東病院消化器内科
【 要旨 】 要旨はありません。
Theme Colorectal carcinoid tumors -- New strategy of treatment
Title Chemotherapy for carcinoid tumors
Author Shuichi Hironaka National Cancer Center Hospital East
Author Shigeaki Yoshida National Cancer Center Hospital East
[ Summary ] Carcinoid tumors have a potential for malignancy, mainly to metastasizing the lymph nodes and liver. The most common symptoms of carcinoid tumors are collectively referred to as the carcinoid syndrome, which is associated with tumor secretion of excessive amounts of major regulatory peptides and amines, such as serotonin and its metabolites. Systemic chemotherapy in patients with unresectable carcinoid tumors has only limited effects on survival and the severity of symptoms. The somatostatin analogue, octreotide has been used for more than a decade in patients with malignant carcinoid syndrome, producing a limited effect on tumor size but with a significant amelioration of clinical symptoms, with few side effects. Hepatic-artery occlusion or embolization in the treatment of liver metastasis is based on the principle that tumors receive most of their blood from the hepatic artery. This treatment has resulted in effective palliation of symptoms in selected patients with substantial side effects. No survival benefit is revealed in patients with carcinoid tumors treated with these treatment modalities. In conclusion, there are now better therapeutic options available for those patients with malignant carcinoid tumors.